CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$4.18
-0.04 (-0.95%)
Open$4.22
Previous Close$4.22
Day High$4.38
Day Low$4.13
52W High$8.21
52W Low$0.91
Volume—
Avg Volume2.86M
Market Cap843.09M
P/E Ratio—
EPS$0.03
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,408.1% upside
Current
$4.18
$4.18
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 111.42M | 98.84M | 145.29M |
| Net Income | -25,393,593 | -20,275,225 | 18.60M |
| Profit Margin | -22.8% | -21.7% | 12.8% |
| EBITDA | -30,859,569 | -26,008,330 | 25.56M |
| Free Cash Flow | — | — | 18.27M |
| Rev Growth | +12.7% | +12.7% | +5.8% |
| Debt/Equity | — | — | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |